Elfabrio

Product

Last mentioned: Mar 18, 2026

Stories mentioning Elfabrio 2

pharma Neutral

Protalix BioTherapeutics Misses Q4 Estimates, Sets Conservative FY26 Outlook

Protalix BioTherapeutics reported a dual miss on revenue and earnings for the latest quarter, reflecting ongoing challenges in the commercial ramp-up of its Fabry disease treatment. Despite the shortfall, the company provided a new fiscal year 2026 outlook as it continues to leverage its plant-based protein expression platform.

2 sources
market-trends Neutral

Protalix BioTherapeutics Misses FY26 Estimates Amid Biotech Market Volatility

Protalix BioTherapeutics reported misses on both top-line and bottom-line estimates for the fiscal year 2026, reflecting ongoing challenges in the rare disease therapeutic market. Despite the shortfall, the company provided a forward-looking outlook for FY26, signaling a focus on long-term clinical development and commercialization of its plant-based protein expression platform.

2 sources